Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$1.86 USD
-0.04 (-2.11%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $1.87 +0.01 (0.54%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
EBS 1.86 -0.04(-2.11%)
Will EBS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
Other News for EBS
Analysts’ Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)
Commit To Purchase Emergent BioSolutions At $2, Earn 37.8% Annualized Using Options
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
Emergent BioSolutions continues to broaden access of NARCAN nasal spray